Cited 0 time in
Postinflammatory hyperpigmentation associated with treatment of solar lentigines using a Q-Switched 532-nm Nd: YAG laser: a multicenter survey
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kang, Hyun Ji | - |
| dc.contributor.author | Na, Jung Im | - |
| dc.contributor.author | Lee, Jong Hee | - |
| dc.contributor.author | Roh, Mi Ryung | - |
| dc.contributor.author | Ko, Joo Yeon | - |
| dc.contributor.author | Chang, Sung Eun | - |
| dc.date.accessioned | 2022-07-13T20:03:53Z | - |
| dc.date.available | 2022-07-13T20:03:53Z | - |
| dc.date.issued | 2017-07 | - |
| dc.identifier.issn | 0954-6634 | - |
| dc.identifier.issn | 1471-1753 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/152001 | - |
| dc.description.abstract | Purpose: To characterize the risk factors of Korean patients for postinflammatory hyperpigmentation (PIH) during treatment of solar lentigines using a Q-switched 532-nm Nd: YAG (QS 532 NY) laser. Materials and Methods: The present retrospective multicenter study was conducted at the dermatology clinics of five tertiary hospitals in Korea. Between October 2007 and January 2013, 516 patients were enrolled and reviewed for clinical features and factors associated with PIH. Results: The overall incidence of PIH was 20.3%. We demonstrated that patients with erythematous lentigines presented with PIH more frequently compared with those without erythematous lentigines. Among several coexisting conditions, facial diffuse dyschromia was significantly associated with PIH. Furthermore, PIH occurred more frequently in patients with invisible pores and velvety skin. However, age, sex, Fitzpatrick skin's phototype and season of treatment showed little association with PIH. Conclusions: When a QS 532 NY laser is used to treat individuals with erythematous lentigines, invisible pores and velvety skin, and facial diffuse dyschromia, clinicians should be cautious and consider preventive measures. | - |
| dc.format.extent | 5 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Taylor & Francis | - |
| dc.title | Postinflammatory hyperpigmentation associated with treatment of solar lentigines using a Q-Switched 532-nm Nd: YAG laser: a multicenter survey | - |
| dc.type | Article | - |
| dc.publisher.location | 영국 | - |
| dc.identifier.doi | 10.1080/09546634.2016.1254330 | - |
| dc.identifier.scopusid | 2-s2.0-84995495552 | - |
| dc.identifier.wosid | 000406114500014 | - |
| dc.identifier.bibliographicCitation | Journal of Dermatological Treatment, v.28, no.5, pp 447 - 451 | - |
| dc.citation.title | Journal of Dermatological Treatment | - |
| dc.citation.volume | 28 | - |
| dc.citation.number | 5 | - |
| dc.citation.startPage | 447 | - |
| dc.citation.endPage | 451 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Dermatology | - |
| dc.relation.journalWebOfScienceCategory | Dermatology | - |
| dc.subject.keywordPlus | GROWTH-FACTOR | - |
| dc.subject.keywordPlus | HUMAN SKIN | - |
| dc.subject.keywordPlus | ASIANS | - |
| dc.subject.keywordPlus | IRRADIATION | - |
| dc.subject.keywordPlus | EFFICACY | - |
| dc.subject.keywordPlus | RISK | - |
| dc.subject.keywordPlus | ACID | - |
| dc.subject.keywordAuthor | Postinflammatory hyperpigmentation | - |
| dc.subject.keywordAuthor | solar lentigo | - |
| dc.subject.keywordAuthor | Q-switched 532-nm Nd: YAG laser | - |
| dc.identifier.url | https://www.tandfonline.com/doi/full/10.1080/09546634.2016.1254330 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
